National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
niddk.nih.govLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
538
Active
65
Phase 3
71
Total enrollment
232,492
Pipeline matrix
Showing 35 of 35 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Epclusa | — | — | — | — | — | 1 | |
| Metreleptin | — | — | — | — | 5 | ||
| 18F-FCH | — | — | — | — | — | 1 | |
| Mirabegron | — | — | — | — | 2 | ||
| Thyrogen | — | — | — | — | 2 | ||
| Dexamethasone | — | — | — | — | — | 3 | |
| 68Ga-DOTATATE | — | — | — | — | — | 2 | |
| 18F-DOPA | — | — | — | — | — | 2 | |
| Teplizumab | — | — | — | — | — | 2 | |
| Antithymocyte Globulin | — | — | — | — | — | 2 | |
| Rituximab | — | — | — | — | — | 2 | |
| Golimumab | — | — | — | — | — | 2 | |
| High-dose methylprednisolone | — | — | — | — | — | 1 | |
| Equine anti-thymocyte globulin | — | — | — | — | — | 1 | |
| Prednisolone | — | — | — | — | — | 1 | |
| Diphenhydramine | — | — | — | — | — | 1 | |
| Methylprednisolone | — | — | — | — | — | 1 | |
| Rosuvastatin | — | — | — | — | — | 1 | |
| VIR-2218 and peginterferon alfa-2a | — | — | — | — | — | 1 | |
| Rezpegaldesleukin | — | — | — | — | — | 1 | |
| Pegvisomant | — | — | — | — | — | 1 | |
| Rituximab-pvvr | — | — | — | — | — | 1 | |
| Abatacept | — | — | — | — | — | 1 | |
| Sterile Sodium Chloride | — | — | — | — | — | 1 | |
| Alpha-lipoic acid | — | — | — | — | — | 1 | |
| Abrocitinib 200 MG Oral | — | — | — | — | — | 1 | |
| Ritlecitinib | — | — | — | — | — | 1 | |
| Oral Cyclosporine | — | — | — | — | — | 1 | |
| Semaglutide | — | — | — | — | — | 1 | |
| Desmopressin | — | — | — | — | — | 1 | |
| 177Lu-DOTA-EB-TATE | — | — | — | — | — | 1 | |
| 68-Gallium-DOTATATE-PET/CT | — | — | — | — | — | 1 | |
| Ketoconazole | — | — | — | — | — | 1 | |
| 68-Gallium Dotatate | — | — | — | — | — | 1 | |
| [18F]-DOPA | — | — | — | — | — | 1 |
Next readouts
- 2019-10-23
- 2026-06-30
- 2026-08
- 2026-08-31
- 2026-09-30
- 2027-03-31
- 2027-07-31
- 2027-07-31
- 2027-12-31
- 2027-12-31
Top conditions
- Obesity88
- Diabetes26
- Healthy Volunteers19
- Diabetes Mellitus, Type 218
- Diabetes Mellitus18
- Type 2 Diabetes13
- Overweight13
- Lipodystrophy12
Frequently asked questions about National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- How many clinical trials does National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) have on ClinicalTrials.gov?
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is listed as the lead sponsor on 538 clinical trials in ClinicalTrials.gov, 65 of which are currently active (recruiting, enrolling, or ongoing).
- How many of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s trials are in Phase 3?
- 71 of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s trials are in Phase 3, spread across 35 active drug programs.
- What therapeutic areas does National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) focus on?
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s most-studied conditions on ClinicalTrials.gov are Obesity, Diabetes, Healthy Volunteers, Diabetes Mellitus, Type 2, Diabetes Mellitus.
- When are National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s next clinical trial readouts?
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has 10 upcoming primary-completion readouts tracked here; the soonest is “Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance”, expected around 2019-10-23.